Compare Comcast Corporation (CMCSA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Viatris Inc — how do they compare? Comcast Corporation trades at $25.63 (market cap $91.02B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Comcast Corporation is far larger — about 4.9× Viatris Inc's market cap, and Comcast Corporation pays the higher dividend (5.15%). Which is the better fit depends on your goals.
| CMCSA | VTRS | |
|---|---|---|
Market Cap | $91.02B | $18.69B |
Sector | Media | Health |
52-Week High | $32.50 | $17.86 |
52-Week Low | $21.92 | $9.49 |
Enterprise Value | $173.74B | $30.80B |
Dividend Yield | 5.15% | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
